Compare Eli Lilly And Co (LLY) vs Opendoor Technologies Inc (OPEN) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Opendoor Technologies (OPEN) trades at $4.415, down 1.89% on the day, reflecting ongoing market skepticism despite recent operational improvements. The stock shows a bearish technical trend with mixed oscillators, while fundamentals reveal persistent losses with a -35.25% net income margin and negative ROE of -173.61%. Revenue has declined from $15.6B in 2022 to $4.37B in 2025, though cash flow turned positive in 2025 at $538M. Recent news highlights CEO focus on housing market challenges and India operations closure to prioritize AI integration.

The outlook remains cautious with high debt and profitability concerns offset by low P/S valuation and analyst 'Hold' consensus. Key risks include interest rate sensitivity and execution of the Opendoor 2.0 model, while potential upside hinges on margin stabilization and seasonal housing rebounds. Investors face a high-risk, speculative opportunity amid structural shifts in real estate tech.